Get the Stockscreener App
26.11
6.61%
1.62
After Hours:
25.71
-0.40
-1.53%
Faeth Therapeutics Inc stock is traded at $26.11, with a volume of 166.64K.
It is up +6.61% in the last 24 hours and up +0.00% over the past month.
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
See More
Previous Close:
$24.49
Open:
$24.38
24h Volume:
166.64K
Relative Volume:
8.44
Market Cap:
$673.08M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+4.44%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$23.00
$26.52
1-Week Range:
$21.24
$26.52
52-Week Range:
$17.50
$28.98
Faeth Therapeutics Inc Stock (FTH) Company Profile
Name
Faeth Therapeutics Inc
Sector
Industry
Phone
(240) 243-8000
Address
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Compare FTH vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FTH
Faeth Therapeutics Inc
|
26.11 | 631.32M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Faeth Therapeutics Inc Stock (FTH) Latest News
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
BTIG Maintains Faeth Therapeutics(FTH.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Faeth Therapeutics CFO Stephenson buys $326,127 in FTH stock By Investing.com - Investing.com Australia
Faeth Therapeutics (FTH) CFO adds 13,634 shares via trust purchases - Stock Titan
Form 4 Faeth Therapeutics, Inc For: 1 July By Investing.com - Investing.com India
Faeth Therapeutics CFO Stephenson buys $326,127 in FTH stock - Investing.com
FTH SEC FilingsFaeth Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition - Stocktwits
FTHFaeth Therapeutics Inc Latest SEC Filings - Finviz
Faeth Therapeutics, Inc.(NasdaqCM:FTH) added to Russell Microcap Value Benchmark Index - marketscreener.com
Faeth Therapeutics, Inc.(NasdaqCM:FTH) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Faeth Therapeutics, Inc.(NasdaqCM: FTH) added to Russell 3000E Growth Benchmark - marketscreener.com
Faeth Therapeutics, Inc.(NasdaqCM: FTH) added to Russell Microcap Index - marketscreener.com
Faeth Therapeutics, Inc.(NasdaqCM: FTH) added to Russell 3000E Value Benchmark - marketscreener.com
Total current assets of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Faeth Therapeutics CFO Stephenson acquires $401,268 in stock By Investing.com - Investing.com Nigeria
Form 4 Faeth Therapeutics, Inc For: 26 June By Investing.com - Investing.com Australia
Faeth Therapeutics CFO Stephenson acquires $401,268 in stock - Investing.com
Faeth Therapeutics (FTH) CFO adds 15,641 shares via trust purchases - Stock Titan
FTH Initiates Coverage On Faeth Therapeutics -- Price Target Set at $57 - GuruFocus
This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Baird Initiates Faeth Therapeutics(FTH.US) With Buy Rating, Announces Target Price $57 - Moomoo
Baird Initiates Faeth Therapeutics at Outperform With $57 Price Target - marketscreener.com
Enterprise value to revenue forward of Faeth Therapeutics, Inc. – MUN:4070 - TradingView
Enterprise value to EBIT forward of Faeth Therapeutics, Inc. – MUN:4070 - TradingView
Baird initiates Faeth Therapeutics stock with outperform rating By Investing.com - Investing.com Nigeria
Price to sales forward of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Baird initiates Faeth Therapeutics stock with outperform rating - Investing.com
Enterprise value to EBITDA forward of Faeth Therapeutics, Inc. – MUN:4070 - TradingView
This Principal Financial Group Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday - Sahm
Price to earnings forward of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Faeth Therapeutics CEO Anand Parikh buys $55,446 in common stock By Investing.com - Investing.com India
FTH | Faeth Therapeutics, Inc. Common Institutional Ownership - Quiver Quantitative
Price to book forward of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
FTH Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Anand Parikh Increases Stake in Faeth Therapeutics Inc - GuruFocus
Faeth Therapeutics CEO Anand Parikh buys $55,446 in common stock - Investing.com UK
Faeth therapeutics CFO Brian C. Stephenson buys $405,920 in stock - Investing.com UK
Faeth therapeutics CFO Brian C. Stephenson buys $405,920 in stock By Investing.com - Investing.com Nigeria
FAETH THERAPEUTICS INC (FTH) Stock Chart - ChartMill
Form 4 Faeth Therapeutics, Inc For: 24 June By Investing.com - Investing.com Australia
FTH | Faeth Therapeutics, Inc. Common Stock Data, Price & News - Quiver Quantitative
Faeth Therapeutics (FTH) CFO adds 17,413 shares via revocable trust purchases - Stock Titan
Faeth Therapeutics CEO buys shares, exercises options | FTH Insider Trading - Stock Titan
Faeth Therapeutics Inc Stock (FTH) Financials Data
There is no financial data for Faeth Therapeutics Inc (FTH). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.17%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):